Table 1.

Dosing and administration of agents for overactive bladder

Drug name	Initial dose	Maximum dose	Adjust for renal or hepatic dysfunction	Geriatric dosing	Adjustment for CYP3A4 interactions
Darifenacin (Enablex)	7.5 mg daily	15 mg daily	7.5 mg daily for moderate hepaticimpairment	N/A	7.5 mg daily
Flavoxate (Urispas)	100–200 mg3–4 times daily	200 mg4 times daily	No	N/A	N/A
Oxybutynin IR (Ditropan)	5 mg2–3 times daily	5 mg4 times daily	No	Initial dose: 2.5 mg 2–3 times daily	N/A
Oxybutynin ER (Ditropan XL)	5–10 mg daily	30 mg daily	No	N/A	N/A
Oxybutynin patch (Oxytrol)	1 patch (36 mg) twice weekly		No	N/A	N/A
Solifenacin (Vesicare)	5 mg daily	10 mg daily	Maximum 5 mg daily for severe renal and moderate hepatic impairment	N/A	5 mg daily
Tolterodine IR (Detrol)	1 mg twice daily	2 mg twice daily	Maximum 1 mg twice daily for severe renal impairment Avoid use in severe hepatic impairment	N/A	1 mg twice daily
Tolterodine ER (Detrol LA)	2 mg daily	4 mg daily	Maximum 2 mg daily for severe renal impairment Avoid use in severe hepatic impairment	N/A	2 mg daily
Trospium (Sanctura)	20 mg daily	20 mg twice daily	Maximum 20 mg daily for severe renal impairment Avoid use in severe hepatic impairment	20 mg daily	N/A

IR indicates immediate-release formulation; ER, extended-release formulation; severe renal impairment, creatinine clearance <30 mL/minute; moderate hepatic impairment, Child-Pugh class B; severe hepatic impairment, Child-Pugh class C; N/A, not applicable.